News
The Regulatory Changes You Don’t See Can Cost You Everything
For pharmaceutical companies, maintaining state licenses is often viewed as a routine compliance obligation. Applications are filed, renewals are submitted, fees are paid, and business moves forward. At least that's how it works when everything goes according...
The Regulatory Shift Virtual Pharmaceutical Companies Can’t Ignore
States are rethinking how virtual manufacturers and wholesalers should be licensed. Is your compliance strategy keeping up? The pharmaceutical industry has embraced a business model that would have seemed almost impossible a generation ago. Today a company can...
The Real Risk of Managing a Pharmaceutical Change of Ownership
In the pharmaceutical industry, a Change of Ownership (CHOW) is far more than a business transaction. Whether a company is acquiring a facility, restructuring corporate ownership, merging operations, or transitioning to a new legal entity, the compliance implications...
The Compliance Risk Most Companies Don’t See Until It’s Too Late
In the pharmaceutical industry, compliance teams spend enormous amounts of time focused on evolving regulations, DSCSA obligations, inspections, and operational continuity. Yet one of the most common compliance risks often comes from something deceptively simple:...
NABP’s New DDA Requirements Just Raised the Bar for Compliance
For years, many organizations approached accreditation with a familiar mindset. Build a solid set of standard operating procedures, document where key requirements are addressed, and ensure everything is organized well enough to pass review. That approach is no longer...
Your License Is a Failure Point: Why State Renewals Are High-Stakes
For many pharmaceutical and medical device companies, state licensing has historically been treated as a routine administrative function. Applications are submitted, renewals are tracked, and documentation is filed away until the next cycle. It has been a predictable...
The FDA Has Drawn a Line in the Sand on DSCSA Compliance
The message is no longer subtle. It is not a warning shot. It is enforcement. A recent action involving U.S. Food and Drug Administration and Pure Indulgence Aesthetics has fundamentally changed the tone around the Drug Supply Chain Security Act. What was once...
The AI Illusion in Pharma Compliance: Why Human Expertise Still Runs the Show
There’s no question that technology is reshaping the pharmaceutical industry. From advanced analytics to AI-driven automation, the promise is compelling: faster workflows, lower costs, and fewer manual errors. In licensing and regulatory compliance, that...
Beyond the Checklist: Why Your Pharmaceutical Compliance Strategy is Failing (and How to Fix It)
If you manage licensing and pharmaceutical compliance for a life sciences or medical device firm, you know the "Sunday Scaries" of the industry: a patchwork of spreadsheets, creeping renewal deadlines, and the constant, low-grade fever of evolving DSCSA requirements....